Animal Models of Autoimmune Hepatitis (AIH)

Autoimmune hepatitis (AIH) is a chronic, immune‑mediated inflammatory liver disease characterized by interface hepatitis, elevated serum transaminases, presence of autoantibodies, and regulatory T‑cell (Treg) dysfunction. Preclinical AIH models recapitulate key pathological features, including T‑cell‑dependent hepatic injury, inflammatory infiltration, and loss of hepatic tolerance.

Download

Key Preclinical Application Areas

Immunosuppressive Drug Efficacy Screening: Evaluation of standard‑of‑care agents (corticosteroids, azathioprine, mycophenolate mofetil, tacrolimus) and novel immunomodulators in both acute ConA‑induced and chronic CYP2D6‑driven AIH models.
Regulatory T‑cell (Treg) Dysfunction & Restoration: Mechanistic studies of Treg instability, impaired suppressive function, and defective IL‑2‑dependent regulation in AIH progression.
Fibrosis and Cirrhosis Intervention: Long‑term chronic AIH models for evaluating anti‑fibrotic compounds, including TGF‑β pathway inhibitors, MMP modulators, and agents targeting hepatic stellate cell activation.
Gut‑liver Axis & Microbiome Modulation: Investigation of intestinal microbiome involvement in AIH pathogenesis using germ‑free or microbiota‑sensitive hybrid systems.

Animal Models of Autoimmune Hepatitis (AIH)

You might be interested in...